Tiziana Life Sciences (NASDAQ:TLSA) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Tiziana Life Sciences (NASDAQ:TLSA) to a hold rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other analysts have also recently issued reports on the company. Wall Street Zen cut Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings downgraded Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tiziana Life Sciences has an average rating of “Reduce”.

Tiziana Life Sciences Stock Performance

NASDAQ:TLSA opened at $1.11 on Tuesday. The stock’s fifty day moving average is $1.30 and its two-hundred day moving average is $1.36. Tiziana Life Sciences has a 52 week low of $1.04 and a 52 week high of $2.60.

Tiziana Life Sciences (NASDAQ:TLSA) last issued its quarterly earnings data on Friday, May 1st. The company reported ($0.28) earnings per share for the quarter. Equities research analysts predict that Tiziana Life Sciences will post -0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Tiziana Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of TLSA. Rachor Investment Advisory Services LLC acquired a new position in Tiziana Life Sciences in the fourth quarter valued at $25,000. Cubist Systematic Strategies LLC purchased a new position in shares of Tiziana Life Sciences during the first quarter worth about $25,000. Marshall Wace LLP acquired a new stake in shares of Tiziana Life Sciences during the second quarter worth about $39,000. HRT Financial LP acquired a new stake in shares of Tiziana Life Sciences during the fourth quarter worth about $36,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Tiziana Life Sciences in the 4th quarter valued at about $59,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.